Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $150M Series D (Mar 2026) led by TCV and Goldman Sachs Alternatives. $1B+ annualized revenue. 7M visits in 2025. 26K providers, 220M covered lives.
Grow Therapy is the largest insurance-covered mental health provider marketplace in the US, connecting 26,000 therapists and psychiatrists with patients across 220 million covered lives. The company raised $150 million in Series D financing in March 2026 led by TCV and Goldman Sachs Alternatives after crossing $1 billion in annualized revenue — rare proof of genuine unit economics in behavioral health, which has historically struggled to achieve profitability at scale.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.